Viridian Therapeutics Initiates Public Stock Offering
January 19, 2024: Viridian Therapeutics, Inc., a burgeoning player in the realm of biotechnology dedicated to pioneering best-in-class medicines for severe and rare diseases, has formally announced the launch of an underwritten public offering of its common stock. This strategic move signifies a pivotal step in propelling Viridian’s ambitious clinical development programs and bolstering its financial resources for future endeavors.
The offering, expected to close on or about January 22, 2024, subject to customary closing conditions, entails selling a yet-to-be-determined number of shares of Viridian’s common stock. The offering price is to be determined through the book-building process, with gross proceeds anticipated to reach approximately $150.0 million. Additionally, Viridian has granted the underwriters a 30-day option to purchase more common shares at the offering price, less underwriting discounts and commissions.
Viridian intends to utilize the proceeds garnered from the offering, combined with its existing cash, cash equivalents, and short-term investments, to fuel the advancement of its robust clinical development portfolio. The company boasts a diversified pipeline of promising drug candidates targeting a spectrum of serious and rare diseases, with a particular focus on central nervous system (CNS) disorders and rare genetic conditions.
Several key clinical milestones lie ahead for Viridian shortly. Phase 3 trials for VRDN-100, a potential first-in-class treatment for Angelman syndrome, are slated to commence in the first half of 2024. Additionally, data from ongoing Phase 2 studies for other lead candidates targeting Parkinson’s disease and Rett syndrome are expected to be reported later this year, potentially shaping the future direction of these development programs.
Furthermore, the influx of capital facilitated by the offering empowers Viridian to explore strategic partnerships and potential acquisitions, enabling it to broaden its therapeutic portfolio and expedite the development of its existing drug candidates.
Viridian’s launch of a public offering reflects the burgeoning confidence in its groundbreaking scientific endeavors and future market potential. With its commitment to tackling unmet medical needs through innovative therapeutics, Viridian is poised to impact the lives of patients grappling with debilitating diseases significantly. As the offering unfolds, stakeholders and industry observers remain keenly focused on its outcome, anticipating its potential to propel Viridian toward its ambitious clinical and commercial goals.
